ArticleAnnals of translational medicine2022

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.

Wenxi Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.